Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of menopausal hormone therapy, according to data published in Rheumatology.

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

The following is a summary of “Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology ...

Selena Gomez has been in the spotlight thanks to her Golden Globe nomination for Emilia Pérez and her engagement to musician ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Columnist Candace Semien applies the concept of radical responsibility to managing lupus and other chronic health conditions.

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...